The stock is listed on the Nasdaq Global Select Market

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a public offering by REGENXBIO Inc. of 4,565,260 shares of common stock at $23.00 per share and pre-funded warrants to purchase 1,521,740 shares of common stock at $22.9999 per pre-funded warrant, for total gross proceeds of approximately $140 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RGNX.”

Based in Rockville, Maryland, REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO and its third-party NAV Technology Platform licensees are applying its NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associate Sierra M. Acosta. Partner David R. Bauer and associates Jordan Khorshad and Emma Willems provided intellectual property advice. The tax team included partner Mario J. Verdolini and associate Ben Silver. All members of the Davis Polk team are based in the New York office.

Copy link to share post